Request a copy of the presentation or its abstract

    1. J. Perkins, R. Balhorn, F.C. Lightstone, and L.C. Zeller. Synthetic Antibodies. American Chemical Society Meeting, Orlando, FL, April 7-11, 2002.
    2. R. Balhorn, J. Perkins, P.A. Burke, F.C. Lightstone, M. Cosman (Balhorn), C.L. Hartmann-Siantar, S.J. DeNardo, M.E. Colvin, T.A. Lehner, J.P. Gregg, H. Albrecht and G.L. DeNardo. Novel Selective High Affinity Ligand (SHAL) “Antibody Mimics” For Lymphoma/Leukemia Imaging and Therapy. Society for Nuclear Medicine 51st Annual Meeting. Philadelphia, Pennsylvania, June 19-23, 2004.
    3. R. Balhorn. Development of Selective High Affinity Ligand (SHAL) Antibody Mimics for Lymphoma/Leukemia Imaging and Therapy. Presented at the Tenth Conference on Cancer Therapy with Antibodies and Immunoconjugates, Princeton, NJ. October 20-23rd, 2004.
    4. R. Balhorn. Synthetic High Affinity Ligands (SHALs): From Detecting Bio-threat Agents to Targeting Tumor Cells. Workshop on Biodefense to Cancer Offense, UC Davis Cancer Center, January 29, 2004.
    5. R. Balhorn, J. Perkins, P. A. Burke, F. C. Lightstone, M. Cosman (Balhorn), C. Venclovas, M. Corzett, S. J. DeNardo, T. A. Lehner, J. P. Gregg, H. Albrecht, and G. L. DeNardo, Development of synthetic high affinity ligands that bind to a structural epitope on the tumor cell receptor HLA-DR10, American Association for Cancer Research (AACR) Meeting Abstracts, p902 – 903, Anaheim, CA April 16-20, 2005
    6. M. Cosman (Balhorn), H. Albrecht, M. Ngu-Schwemlein, M. Corzett, S. Hok, C. Dolan, J. Perkins, S.J. DeNardo, G.L. DeNardo and R. Balhorn. Recombinant HLA-DR10 β-subunit for Developing Novel Targeting Agents for Non-Hodgkin’s Lymphoma. Presented at the Eleventh Conference on Cancer Therapy with Antibodies and Immunoconjugates, Parsippany, NJ October 12-14, 2006.
    7. R. Balhorn,  S. Hok, P. A. Burke, F. C. Lightstone, M. Cosman (Balhorn), A. Zemla, G. Mirick, J. Perkins, A. Natarajan , M. Corzett, S. J. DeNardo, T. A. Lehner, H. Albrecht, J.P. Gregg and G. L. DeNardo. Biodistribution and pharmacokinetics of selective high affinity ligands (SHALs) in mice bearing Raji xenografts. Presented at the Eleventh Conference on Cancer Therapy with Antibodies and Immunoconjugates, Parsippany, NJ, Oct. 12-14, 2006.
    8. S. Hok, A. Natarajan, R. Balhorn, S. J. DeNardo, G. L. DeNardo and J. Perkins. Synthesis and Radiolabeling of Selective High Affinity Ligands Designed to Target Non-Hodgkin’s Lymphoma and Leukemia. Presented at the Eleventh Conference on Cancer Therapy with Antibodies and Immunoconjugates, Parsippany, NJ October 12-14, 2006.
    9. R. Balhorn, D. Cordes, M. Corzett, M. Cosman (Balhorn), S. Hok, F. Lightstone, J. Perkins, J. Ulloa, A. Zemla, C. Zhou, H. Albrecht, D. DeNardo, S. DeNardo, K. Lam, A. Lehman, L. Miers, G. Mirick, A. Natarajan. Development of SHALs (Selective High Affinity Ligands) for Cancer Therapy and Biodefense. Presented at the Second Annual Biomedical Technology Program sponsored by the University of California at Davis. Lodi, CA December 7, 2006.
    10. R. Balhorn, M. Cosman (Balhorn), S. Hok, F. Lightstone, J. Perkins, G. DeNardo, S. DeNardo, K. Lam, and A. Lehman.  Synthetic High Affinity Ligands as Antibody Mimics. Presented at the 121st AOAC (Association of Official Analytical Chemists) International Meeting, Anaheim, CA, Sept 16-20, 2007.
    11. R. Balhorn, M. Cosman (Balhorn), H.-J. Kung, K. Lam, E. Lau, R. Law, A. Lehman and F. Lightstone. Development of SHALs as Diagnostics and Therapeutics: Future Sumo SHALs. Presented at the University of California Cancer Center Retreat, Granlibaken Conference Center, Lake Tahoe, September 20, 2008.
    12. G. DeNardo, A. Natarajan, S. Hok, G. Mirick, S. DeNardo, M. Corzett, V. Sysko, J. Lehmann, L. Beckett, R. Balhorn. Novel nanomolecular HLA-DR10 antibody mimics provide a potent system for molecular therapy and imaging. Presented at the Society for Nuclear Medicine, New Orleans, LA, June 14-18, 2008.
    13. A. Natarajan, G. DeNardo, S. Hok, G. Mirick, S. DeNardo, M. Corzett, V. Sysko, J. Lehmann, L. Beckett and R. Balhorn. Lymphoma targeting HLA-DR10 antibody mimics: A novel multiligand system for molecular therapy and imaging. Presented at the University of California Davis Cancer Center, August 2008.
    14. R. Balhorn, M. Corzett, M. (Cosman) Balhorn, S. Hok, F. Lightstone, J. Perkins, G. DeNardo, S. DeNardo, H. Albrecht, P. Burke, L. Miers, G. Mirick and A. Natarajan. Development of the Selective High Affinity Ligand SH-7139 as a Potential Therapeutic for Non-Hodgkin’s Lymphoma. Presented at the Fred Hutchinson Cancer Research Center, Seattle, WA, April 7, 2010.
    15. R. Balhorn and M. (Cosman) Balhorn, SHALs: A New Paradigm for Therapeutic Agents: 2-day Workshop, American University in Cairo, Cairo, Egypt, June 27-28, 2010
    16. R. Balhorn, R Rebhun, S Hok, R Baum, J Sanger and M. (Cosman) Balhorn, Biotinylated Analog of a Selective High Affinity Ligand (SHAL) Therapeutic as a Companion Diagnostic for Prescreening non-Hodgkin’s  Lymphoma, American Association for Cancer Research (AACR) Annual Meeting, Chicago, IL, April 3, 2012.
    17. M.C. Prieto Conaway, J Sutton; T Stratton, LJ Wang; K Comstock, S Hok, R Balhorn, Impurity Analysis of Selective High Affinity Ligands: Comparison of Bench-Scale vs. Production Syntheses by Label Free Differential Analysis, American Society for Mass Spectrometry, Vancouver, Canada, May 20 -24, 2012.
    18. M.C. Prieto Conaway, J. Sutton, T. Stratton, L. J. Wang, K. Comstock, S. Hok, R. Balhorn, Impurity Analysis of Selective High-Affinity Ligands: Comparison of Bench-Scale vs. Production Syntheses by Label-Free Differential Analysis, LCMS Montreux Symposium, Montreux Switzerland, Nov 6-12, 2012.
    19. R. Balhorn, S. Hok, M. Rabe, J. Brooks and M. (Cosman) Balhorn, Pilot Toxicology Study of the B-cell Lymphoma Drug Candidate SH7139 Demonstrates Lack of Toxicity in Beagles, American Association for Cancer Research (AACR) Annual Meeting, Washington DC, April 9, 2013.
    20. M. (Cosman) Balhorn, S. Hok, G. Zhang, H. Shen, and R. Balhorn, A Modular Synthetic Approach for Producing SH7139, a New Drug Candidate for Treating B-cell Lymphoma, Adapts Well to Scale-up, American Association for Cancer Research (AACR) Annual Meeting, Washington DC, April 9, 2013.
    21. R. Balhorn, G. Mirick, L. Beckett, J. Li, S. Hok, and M. (Cosman) Balhorn. Effect of Route and Dosing Regimen on Efficacy of SH7139 in Mouse Burkitt’s Lymphoma Xenografts. American Association for Cancer Research Annual Meeting, San Diego, CA, April 7, 2014.
    22. M. (Cosman) Balhorn, G. Mirick, D. Cheng, Z. Ma, E.Y. Lau, S. Hok, G.L. DeNardo, and R. Balhorn. Intracellular Uptake and Metabolism of SH7139: Is it a Targeted Prodrug for B-cell Lymphoma? American Association for Cancer Research Annual Meeting, San Diego, CA, April 9, 2014.
    23. M. (Cosman) Balhorn. Intracellular Uptake and Metabolism of the Antibody Mimetic SH7139 Leads to an ADC-like Tumor Killing Mechanism. 6th Annual International Congress of Antibodies, Dalian, China, April 26, 2014.
    24. R. Balhorn. Development of Small Molecule Anibody Mimics as Therapeutics and Companion Diagnostics. 6th Annual International Congress of Antibodies, Dalian, China, April 27, 2014.
    25. R. Balhorn and M. (Cosman) Balhorn. Targeted Small Molecule Drugs for Non-Hodgkin’s Lymphoma That Function Similar to Antibody Drug Conjugates and Pro-Drugs. 6th Annual International Congress of Antibodies, BIT Project Matchmaking Event, Dalian, China, April 26, 2014.
    26. M. (Cosman) Balhorn, S. Hok, and R. Balhorn. Multiple mechanisms of action may contribute to the lymphoma cell-killing activity of SH7139. American Association for Cancer Research Annual Meeting, Philadelphia, PA,  April  22, 2015.
    27. R. Balhorn,  S.Hok and M. (Cosman) Balhorn. Physical and metabolic stability of SH7139, a new drug candidate for non-Hodgkin;s lymphoma targeting HLA-DR10. American Association for Cancer Research Annual Meeting, Philadelphia, PA,  April  21, 2015.
    28. M. (Cosman) Balhorn, R. Balhorn. Metabolism studies of SH7139, a small molecule drug targeting B-cell malignancies overexpressing HLA-DR10, confirm its prodrug function. American Association for Cancer Research Annual Meeting, New Orleans, LA  April  18, 2016.
    29. R. Balhorn, A.J. van Adrichem, S. Hok, M. (Cosman). Balhorn. Inhibition of Rac1 GTPase activity by SH7139, a new drug candidate for non-Hodgkin’s lymphoma targeting HLA-DR10. American Association for Cancer Research Annual Meeting, New Orleans, LA  April  19, 2016.
    30. M. (Cosman) Balhorn, R. Balhorn. Therapeutic applications of the selective high affinity ligand drug SH7139 may extend beyond NHL to many other types of solid tumors. American Association for Cancer Research Annual Meeting, Washington, DC,  April  3, 2017.
    31. R. Balhorn, M. (Cosman) Balhorn. Pre-clinical toxicology and safety of SH7139, the first of a new class of targeted therapeutics for non-Hodgkin’s lymphoma and other cancers. American Association for Cancer Research Annual Meeting, Washington, DC,  April  4, 2017.
    32. Maria C. Prieto Conaway, Kerry M. Hassell, Rod Balhorn. PaperSpray Technology for the Study of Selective High Affinity Ligands (SHALs) and their Metabolites. 65th ASMS Conference on Mass Spectrometry and Allied Topics, Indianapolis, IN, June 8, 2017